CRSP CRISPR Therapeutics AG - Common Shares

NASDAQ · Biotechnology · Voir sur SEC EDGAR ↗
$56,87
Prix · Aoû 19, 2026
Données fondamentales au Aoû 3, 2026
Fourchette 52 semaines
$44–$78
37% of range
Note des analystes
HOLD
29 analysts
Objectif de cours
$88
+54% upside
P/E (TTM)
-8.8
ROE
-32.0%
Marge nette
-16569.8%

À propos de CRISPR Therapeutics AG - Common Shares Présentation de l'entreprise depuis Wikipedia

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

Lire la suite

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

History

CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.

CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.

CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.

Products

CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.

Exa-cel

Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.

Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗

Wikidata ↗

CRSP Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines

Prix
$56.87
Capitalisation Boursière
$5.45B
P/E (TTM)
-8.8
BPA (TTM)
$-6.47
Revenus (TTM)
$4M
Rendement div.
—
ROE
-32.0%
Dette/Capitaux propres
—
Fourchette 52 semaines
$44 – $78

CRSP Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue

Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA

Revenus et bénéfice net $4M
10-point trend, -32.0%
2016-12-31 → 2025-12-31
BPA $-6.47
9-point trend, -278.4%
2017-12-31 → 2025-12-31
Flux de trésorerie libre $-346M
10-point trend, -493.1%
2016-12-31 → 2025-12-31
Marges -16569.8%

Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?

Métrique
Tendance sur 5 ans
CRSP
Médiane des pairs
P/E (TTM)
5-point trend, -150.3%
-8.8
—
P/S (TTM)
5-point trend, +22368.1%
1553.7
56.3
P/B
5-point trend, +7.6%
2.8
3.0
Price / FCF (Cours / FCF)
5-point trend, -213.9%
-15.8
—

Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC

Métrique
Tendance sur 5 ans
CRSP
Médiane des pairs
Operating Margin (Marge d'exploitation)
5-point trend, -46483.3%
-18933.7%
—
Net Profit Margin (Marge nette)
5-point trend, -40239.9%
-16569.8%
-1643.9%
ROA
5-point trend, -256.5%
-25.8%
-40.2%
ROE
5-point trend, -308.2%
-32.0%
-75.3%
ROIC
5-point trend, -324.7%
-34.8%
—

Santé financière Dette, liquidité, solvabilité — solidité du bilan

Métrique
Tendance sur 5 ans
CRSP
Médiane des pairs
Current Ratio (Ratio de liquidité)
5-point trend, -34.0%
13.3
6.7
Quick Ratio (Ratio de liquidité réduite)
5-point trend, -33.2%
13.2
—

Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans

Métrique
Tendance sur 5 ans
CRSP
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
5-point trend, -99.6%
-90.6%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
5-point trend, -99.6%
43.1%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
5-point trend, -99.6%
37.3%
—

Indicateurs par action BPA, valeur comptable par action, flux de trésorerie par action, dividende par action

Métrique
Tendance sur 5 ans
CRSP
Médiane des pairs
EPS (Diluted) (BPA (Dilué))
5-point trend, -237.7%
$-6.47
—

Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances

Métrique
Tendance sur 5 ans
CRSP
Médiane des pairs

CRSP Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse

ACHAT 29 analystes
  • Achat fort 6 20,7%
  • Achat 11 37,9%
  • Conserver 12 41,4%
  • Vente 0 0,0%
  • Vente forte 0 0,0%

Objectif de cours à 12 mois

18 analystes · 2026-08-15
Objectif médian $80.00 +40,7%
Objectif moyen $87.56 +54,0%

Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats

Surprise Moyenne
0.01%
Période EPS Actual BPA est. Surprise
30 juin 2026 $-0.94 $-1.22 0.28%
31 mars 2026 $-1.28 $-1.25 -0.03%
31 décembre 2025 $-1.37 $-1.18 -0.19%
30 septembre 2025 $-1.17 $-1.29 0.12%
30 juin 2025 $-1.29 $-1.45 0.16%
31 mars 2025 $-1.58 $-1.28 -0.30%

Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur

Ticker Capitalisation Boursière P/E Revenus Année/Année Marge Nette ROE Marge Brute
CRSP $5.03B -8.1 -90.6% -16569.8% -32.0% —
MLTX — -3.7 — — -60.5% —
ACIU — — — — — —
ADCT $444M -3.2 14.8% -175.3% 74.1% —

Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie

Compte de résultat 15
Données annuelles Compte de résultat pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
Revenue 11-point trend, +1321.1% $4M $37M $371M $1M $915M $719.0K $290M $3M $41M $5M $247.0K
R&D Expense 11-point trend, +2165.2% $285M $310M $387M $462M $341M $221M $179M $114M $70M $42M $13M
SG&A Expense 11-point trend, +448.7% $74M $73M $76M $102M $100M $86M $63M $48M $36M $31M $13M
Operating Expenses 11-point trend, +2471.9% $668M $504M $594M $674M $541M $355M $243M $162M $106M $73M $26M
Operating Income 11-point trend, -2483.0% $-665M $-467M $-223M $-673M $374M $-354M $47M $-159M $-65M $-68M $-26M
Interest Income 3-point trend, +347.6% · $104M $76M $23M · · · · · · ·
Other Non-op 11-point trend, +541187.5% $87M $104M $72M $23M $6M $6M $26M $-1M $-197.0K $79M $16.0K
Pretax Income 11-point trend, -2138.4% $-578M $-363M $-151M $-650M $380M $-348M $67M $-164M $-67M $-23M $-26M
Income Tax 11-point trend, +51814.3% $4M $4M $3M $-325.0K $2M $809.0K $448.0K $553.0K $2M $484.0K $7.0K
Net Income 11-point trend, -2180.5% $-582M $-366M $-154M $-650M $378M $-349M $67M $-165M $-68M $-23M $-26M
EPS (Basic) 9-point trend, -278.4% $-6.47 $-4.34 $-1.94 $-8.36 $4.97 $-5.29 $1.23 $-3.44 $-1.71 · ·
EPS (Diluted) 9-point trend, -278.4% $-6.47 $-4.34 $-1.94 $-8.36 $4.70 $-5.29 $1.17 $-3.44 $-1.71 · ·
Shares (Basic) 9-point trend, +124.5% 89,925,109 84,359,126 79,220,930 77,746,575 75,948,686 65,949,672 54,392,304 47,964,368 40,057,365 · ·
Shares (Diluted) 9-point trend, +124.5% 89,925,109 84,359,126 79,220,930 77,746,575 80,393,496 65,949,672 56,932,798 47,964,368 40,057,365 · ·
EBITDA 10-point trend, -859.9% $-645M $-447M $-203M $-649M $391M $-345M $51M $-155M $-62M $-67M ·
Bilan 25
Données annuelles Bilan pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
Cash & Equivalents 11-point trend, +122.8% $348M $298M $389M $212M $923M $1.17B $944M $457M $240M $316M $156M
Short-term Investments 7-point trend, +1628269000.00 $1.63B $1.61B $1.30B $1.60B $1.46B $522M $0 · · · ·
Receivables 11-point trend, -100.0% $0 $25M $200M $0 $305.0K $144.0K $99.0K $88.0K $3M $3M $339.0K
Prepaid Expense 11-point trend, +1722.8% $10M $8M $14M $38M $38M $26M $44M $10M $6M $2M $540.0K
Current Assets 11-point trend, +1166.0% $1.99B $1.94B $1.91B $1.85B $2.42B $1.72B $988M $466M $248M $320M $157M
PP&E (Net) 11-point trend, +8623.7% $116M $134M $152M $164M $138M $42M $31M $18M $19M $21M $1M
PP&E (Gross) 11-point trend, +14678.8% $207M $206M $205M $197M $175M $63M $43M $26M $23M $22M $1M
Accum. Depreciation 11-point trend, +126361.1% $91M $72M $53M $34M $38M $21M $12M $7M $4M $942.0K $72.0K
Intangibles 10-point trend, -100.0% · $0 $16.0K $71.0K $125.0K $180.0K $235.0K $289.0K $344.0K $399.0K $454.0K
Other Non-current Assets 11-point trend, +24026.7% $24M $16M $2M $5M $5M $1M $1M $669.0K $606.0K $198.0K $101.0K
Total Assets 11-point trend, +1320.9% $2.27B $2.24B $2.23B $2.24B $2.75B $1.83B $1.07B $489M $271M $345M $159M
Accounts Payable 11-point trend, +603.2% $11M $15M $38M $27M $15M $9M $6M $5M $2M $5M $2M
Accrued Liabilities 11-point trend, +960.6% $89M $41M $45M $78M $91M $54M $30M $21M $11M $16M $8M
Current Liabilities 11-point trend, +1368.4% $149M $88M $109M $121M $120M $94M $57M $28M $15M $22M $10M
Capital Leases 7-point trend, +327.2% $188M $206M $223M $228M $213M $50M $44M · · · ·
Other Non-current Liabilities 11-point trend, +2085.8% $6M $3M $958.0K $6M $7M $8M $14M $243.0K $314.0K $189.0K $281.0K
Total Liabilities 11-point trend, +176.9% $343M $310M $347M $368M $352M $164M $127M $97M $84M $112M $124M
Long-term Debt $0 · · · · · · · · · ·
Common Stock 11-point trend, +1605.5% $3M $3M $2M $2M $2M $2M $2M $2M $1M $1M $181.0K
Retained Earnings 11-point trend, -5644.0% $-1.95B $-1.37B $-1000M $-846M $-196M $-574M $-225M $-292M $-125M $-57M $-34M
Treasury Stock 11-point trend, +60000.00 $60.0K $62.0K $62.0K $63.0K $63.0K $63.0K $63.0K $57.0K $0 $0 $0
AOCI 11-point trend, +60362.5% $5M $2M $2M $-16M $-5M $-83.0K $7.0K $-8.0K $14.0K $-26.0K $-8.0K
Stockholders' Equity 11-point trend, +6704.8% $1.92B $1.93B $1.88B $1.88B $2.40B $1.66B $939M $392M $188M $233M $-29M
Liabilities + Equity 11-point trend, +1320.9% $2.27B $2.24B $2.23B $2.24B $2.75B $1.83B $1.07B $489M $271M $345M $159M
Shares Outstanding 11-point trend, +1634.7% 95,894,341 85,741,981 80,044,378 78,512,450 76,990,066 73,914,844 60,783,799 51,852,862 40,592,248 39,719,434 5,528,079
Flux de trésorerie 14
Données annuelles Flux de trésorerie pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
D&A 11-point trend, +15237.8% $19M $19M $20M $24M $18M $9M $5M $4M $3M $925.0K $127.0K
Stock-based Comp 11-point trend, +1867.9% $72M $87M $81M $98M $102M $66M $44M $35M $19M $11M $4M
Deferred Tax 11-point trend, +1794.4% $915.0K $-484.0K $-424.0K $-1M $2M $409.0K $-34.0K $6.0K $180.0K $-137.0K $-54.0K
Other Non-cash 10-point trend, +428.3% $144M $118M $-207M $33M $39M $35M $-59M $30M $-24M $-44M ·
Operating Cash Flow 11-point trend, -680.6% $-345M $-143M $-260M $-496M $539M $-238M $57M $-96M $-70M $-53M $59M
CapEx 11-point trend, -20.8% $914.0K $2M $9M $37M $82M $18M $7M $3M $8M $3M $1M
Investing Cash Flow 10-point trend, -199.8% $-32M $-280M $375M $-259M $-1.04B $-541M $1M $-3M $-8M $32M ·
Stock Issued 10-point trend, +347.0% $398M $301M $33M $970.0K $213M $982M $415M $307M $0 $89M ·
Stock Repurchased · · · · · · · $57.0K · · ·
Net Stock Activity 8-point trend, +29.7% $398M $301M $33M $970.0K $213M $982M $415M $307M · · ·
Financing Cash Flow 10-point trend, +132.5% $426M $332M $63M $39M $251M $1.02B $431M $316M $3M $183M ·
Net Change in Cash 11-point trend, -68.2% $49M $-91M $177M $-716M $-246M $237M $489M $217M $-76M $162M $155M
Taxes Paid $3M · · · · · · · · · ·
Free Cash Flow 10-point trend, -493.1% $-346M $-145M $-270M $-533M $457M $-257M $50M $-99M $-78M $-58M ·
Rentabilité 7
Données annuelles Rentabilité pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
Operating Margin 10-point trend, -1335.1% -18933.7% -1250.4% -60.0% -56190.4% 40.8% -49295.5% 16.1% -5087.8% -157.7% -1319.3% ·
Net Margin 10-point trend, -3591.9% -16569.8% -981.5% -41.4% -54271.7% 41.3% -48520.9% 23.1% -5281.1% -166.7% -448.8% ·
Pretax Margin 10-point trend, -3642.9% -16466.2% -971.9% -40.6% -54298.8% 41.5% -48408.3% 23.2% -5263.4% -162.5% -439.9% ·
EBITDA Margin 10-point trend, -1312.2% -18378.7% -1198.8% -54.6% -54172.7% 42.8% -48018.2% 17.8% -4975.2% -150.3% -1301.4% ·
ROA 10-point trend, -180.8% -25.8% -16.4% -6.9% -26.0% 16.5% -24.1% 8.6% -43.4% -22.2% -9.2% ·
ROE 10-point trend, -40.7% -32.0% -18.9% -8.5% -34.0% 15.4% -23.2% 8.7% -40.8% -32.5% -22.8% ·
ROIC 10-point trend, -16.5% -34.8% -24.4% -12.0% -35.9% 15.5% -21.3% 4.9% -40.7% -35.3% -29.9% ·
Liquidité et Solvabilité 2
Données annuelles Liquidité et Solvabilité pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
Current Ratio 10-point trend, -8.5% 13.3 22.1 17.5 15.3 20.2 18.2 17.3 16.8 17.1 14.6 ·
Quick Ratio 10-point trend, -8.5% 13.2 22.0 17.4 15.0 19.8 17.9 16.5 16.5 16.7 14.5 ·
Efficacité 2
Données annuelles Efficacité pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
Asset Turnover 10-point trend, -92.2% 0.0 0.0 0.2 0.0 0.4 0.0 0.4 0.0 0.1 0.0 ·
Receivables Turnover 10-point trend, -90.5% 0.3 0.3 3.7 7.9 4075.6 5.9 3097.2 2.3 14.2 3.0 ·
Par action 5
Données annuelles Par action pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
Book Value / Share 10-point trend, +241.9% $20.04 $22.53 $23.52 $23.89 $31.17 $22.52 $15.46 $7.56 $4.63 $5.86 ·
Revenue / Share 7-point trend, -99.2% $0.04 $0.44 $4.69 $0.02 $11.38 $0.01 $5.09 · · · ·
Cash Flow / Share 7-point trend, -485.4% $-3.84 $-1.69 $-3.29 $-6.38 $6.70 $-3.61 $1.00 · · · ·
Cash / Share 10-point trend, -54.4% $3.62 $3.48 $4.87 $2.70 $11.99 $15.81 $15.53 $8.81 $5.91 $7.94 ·
EPS (TTM) 10-point trend, +8.2% $-6.47 $-4.34 $-1.94 $-8.36 $4.70 $-5.29 $1.17 $-3.44 $-1.71 $-7.05 ·
Taux de croissance 3
Données annuelles Taux de croissance pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
Revenue YoY 5-point trend, -100.1% -90.6% -90.0% 30885.5% -99.9% 127154.9% · · · · · ·
Revenue CAGR 3Y 3-point trend, -93.9% 43.1% -65.6% 702.2% · · · · · · · ·
Revenue CAGR 5Y 37.3% · · · · · · · · · ·
Valorisation (TTM) 10
Données annuelles Valorisation (TTM) pour CRSP
Métrique Tendance 20252024202320222021202020192018201720162015
Revenue TTM 10-point trend, -32.0% $4M $37M $371M $1M $915M $719.0K $290M $3M $41M $5M ·
Net Income TTM 10-point trend, -2409.4% $-582M $-366M $-154M $-650M $378M $-349M $67M $-165M $-68M $-23M ·
Market Cap 10-point trend, +524.9% $5.03B $3.37B $5.01B $3.19B $5.83B $11.32B $3.70B $1.48B $953M $805M ·
P/E 10-point trend, -182.0% -8.1 -9.1 -32.3 -4.9 16.1 -28.9 52.1 -8.3 -13.7 -2.9 ·
P/S 10-point trend, +819.4% 1432.7 90.4 13.5 2664.0 6.4 15740.1 12.8 474.2 23.2 155.8 ·
P/B 10-point trend, -24.3% 2.6 1.7 2.7 1.7 2.4 6.8 3.9 3.8 5.1 3.5 ·
P / Tangible Book 6-point trend, -61.5% 2.6 1.7 2.7 1.7 2.4 6.8 · · · · ·
P / Cash Flow 10-point trend, -0.2% -14.6 -23.6 -19.2 -6.4 10.8 -47.5 65.3 -15.4 -13.6 -14.5 ·
P / FCF 10-point trend, -5.4% -14.5 -23.3 -18.6 -6.0 12.8 -44.1 74.1 -15.0 -12.2 -13.8 ·
Earnings Yield 10-point trend, +64.5% -12.3% -11.0% -3.1% -20.6% 6.2% -3.5% 1.9% -12.0% -7.3% -34.8% ·

États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années

Compte de résultat
2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenu $4M$37M$371M$1M$915M
Marge d'exploitation % -18933.7%-1250.4%-60.0%-56190.4%40.8%
Résultat net $-582M$-366M$-154M$-650M$378M
BPA dilué $-6.47$-4.34$-1.94$-8.36$4.70
Bilan
2025-12-312024-12-312023-12-312022-12-312021-12-31
Ratio de liquidité 13.322.117.515.320.2
Ratio de liquidité réduite 13.222.017.415.019.8
Flux de trésorerie
2025-12-312024-12-312023-12-312022-12-312021-12-31
Flux de trésorerie libre $-346M$-145M$-270M$-533M$457M

Dernières actualités Actualités récentes mentionnant cette entreprise

Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets

📊

Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.

Votre sélection est enregistrée et vous suit sur tous les tickers.

Détenteurs institutionnels (13F) 574 déclarants · $3.3B total · Au 30 juin 2026

Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.

Activité institutionnelle — Q2 2026 vs trimestre précédent
Nouvelles positions Positions clôturées Augmenté Diminué Variation nette des actions
89 (-7 vs T. préc.) 47 (-12 vs T. préc.) 148 (-24 vs T. préc.) 146 (+21 vs T. préc.) +2.9M

Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.

Institution Valeur Actions % de 13F suivies Type
ARK Investment Management LLC $515 999 631 9 460 939 15,58% Actions
Orbis Allan Gray Ltd $296 334 582 5 433 344 8,95% Actions
Capital World Investors $259 039 094 4 749 525 7,82% Actions
STATE STREET CORP $235 703 664 4 321 666 7,12% Actions
GSK plc $175 652 997 3 220 627 5,30% Actions
GEODE CAPITAL MANAGEMENT, LLC $117 453 717 2 153 015 3,55% Actions
SR One Capital Management, LP $111 194 134 2 038 763 3,36% Actions
TWO SIGMA INVESTMENTS, LP $108 459 389 1 988 621 3,27% Actions
Sumitomo Mitsui Trust Group, Inc. $93 848 832 1 720 734 2,83% Actions
Amova Asset Management Americas, Inc. $93 762 487 1 720 097 2,83% Actions
EcoR1 Capital, LLC $75 771 113 1 389 276 2,29% Actions
Capital International Investors $69 178 918 1 268 407 2,09% Actions
VANGUARD CAPITAL MANAGEMENT LLC $64 457 935 1 181 847 1,95% Actions
NEA Management Company, LLC $57 734 408 1 058 570 1,74% Actions
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $57 694 430 1 057 837 1,74% Actions
FMR LLC $53 577 751 982 357 1,62% Actions
D. E. Shaw & Co., Inc. $48 748 506 893 812 1,47% Actions
VANGUARD PORTFOLIO MANAGEMENT LLC $35 380 807 648 713 1,07% Actions
UBS Group AG $32 419 612 594 419 0,98% Actions
VANGUARD FIDUCIARY TRUST CO $31 089 982 570 040 0,94% Actions
VANGUARD GROUP INC $27 714 225 528 494 0,84% Actions
CITADEL ADVISORS LLC $25 404 514 465 796 0,77% Actions
BANK OF AMERICA CORP /DE/ $23 509 740 431 055 0,71% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $23 298 288 427 178 0,70% Actions
MILLENNIUM MANAGEMENT LLC $20 836 025 382 032 0,63% Actions
IQ EQ FUND MANAGEMENT (IRELAND) Ltd $20 833 789 381 991 0,63% Actions
SUSQUEHANNA INTERNATIONAL GROUP, LLP $18 456 336 338 400 0,56% Option de vente
SUSQUEHANNA INTERNATIONAL GROUP, LLP $17 763 678 325 700 0,54% Option d'achat
Logos Global Management LP $16 362 000 300 000 0,49% Actions
CITADEL ADVISORS LLC $15 822 054 290 100 0,48% Option de vente
Squarepoint Ops LLC $15 641 472 286 789 0,47% Actions
NORGES BANK $14 767 032 270 756 0,45% Actions
CITADEL ADVISORS LLC $13 973 148 256 200 0,42% Option d'achat
GOLDMAN SACHS GROUP INC $12 748 193 233 740 0,38% Actions
JANE STREET GROUP, LLC $12 566 016 230 400 0,38% Option d'achat
PEAK6 LLC $11 633 382 213 300 0,35% Option de vente
Swiss National Bank $9 228 168 169 200 0,28% Actions
Susquehanna Portfolio Strategies, LLC $8 945 978 164 026 0,27% Actions
TWO SIGMA ADVISERS, LP $8 516 256 162 400 0,26% Actions
LPL Financial LLC $8 376 280 153 581 0,25% Actions
Bank of New York Mellon Corp $8 337 366 152 867 0,25% Actions
DIMENSIONAL FUND ADVISORS LP $8 301 261 152 205 0,25% Actions
Versant Venture Management, LLC $8 117 243 148 831 0,25% Actions
Pictet Asset Management Holding SA $7 989 776 142 213 0,24% Actions
Life Cycle Investment Partners Ltd $7 836 962 143 692 0,24% Actions
TD Asset Management Inc $7 777 513 142 602 0,23% Actions
AMERICAN CENTURY COMPANIES INC $7 606 257 139 462 0,23% Actions
RAYMOND JAMES FINANCIAL INC $7 230 750 132 577 0,22% Actions
RHUMBLINE ADVISERS $6 627 197 121 511 0,20% Actions
SFE Investment Counsel $6 229 434 16 700 0,19% Option de vente
Private Advisor Group, LLC $6 060 980 111 129 0,18% Actions
EverSource Wealth Advisors, LLC $6 032 669 110 610 0,18% Actions
CONGRESS ASSET MANAGEMENT CO $5 969 567 109 453 0,18% Actions
BlackRock, Inc. $5 937 061 108 857 0,18% Actions
D. E. Shaw & Co., Inc. $5 901 228 108 200 0,18% Option d'achat
Campbell & CO Investment Adviser LLC $5 864 632 107 529 0,18% Actions
JANE STREET GROUP, LLC $5 852 142 107 300 0,18% Option de vente
California Public Employees Retirement System $5 599 567 102 669 0,17% Actions
CAPITAL INTERNATIONAL SARL $5 521 521 101 238 0,17% Actions
Affinity Asset Advisors, LLC $5 454 000 100 000 0,16% Actions
ALLIANCEBERNSTEIN L.P. $5 439 011 114 337 0,16% Actions
CLOUGH CAPITAL PARTNERS L P $5 363 300 98 337 0,16% Actions
Zurcher Kantonalbank (Zurich Cantonalbank) $5 172 465 94 838 0,16% Actions
Slow Capital, Inc. $5 066 439 92 894 0,15% Actions
CAPITAL FUND MANAGEMENT S.A. $4 867 258 89 242 0,15% Actions
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $4 815 606 101 232 0,15% Actions
VANGUARD ASSET MANAGEMENT, Ltd $4 720 437 86 550 0,14% Actions
GROUP ONE TRADING LLC $4 638 082 85 040 0,14% Actions
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. $4 575 742 83 897 0,14% Actions
STATE OF MICHIGAN RETIREMENT SYSTEM $4 502 113 82 547 0,14% Actions
Concurrent Investment Advisors, LLC $4 497 728 82 467 0,14% Actions
WELLS FARGO & COMPANY/MN $4 309 151 79 009 0,13% Actions
Fisher Asset Management, LLC $4 251 957 77 960 0,13% Actions
Trexquant Investment LP $4 225 268 77 471 0,13% Actions
COMMONWEALTH EQUITY SERVICES, LLC $4 194 122 76 900 0,13% Actions
JONES FINANCIAL COMPANIES LLLP $4 055 652 73 847 0,12% Actions
Man Group plc $3 992 001 73 194 0,12% Actions
PEAK6 LLC $3 834 162 70 300 0,12% Option d'achat
ENVESTNET ASSET MANAGEMENT INC $3 822 196 70 081 0,12% Actions
ALGERT GLOBAL LLC $3 593 095 65 880 0,11% Actions
Walleye Trading LLC $3 528 738 64 700 0,11% Option de vente
MILLENNIUM MANAGEMENT LLC $3 146 958 57 700 0,10% Option d'achat
CAPITAL INTERNATIONAL LTD /CA/ $3 057 840 56 066 0,09% Actions
NOMURA HOLDINGS INC $3 055 713 56 027 0,09% Actions
Rafferty Asset Management, LLC $3 045 132 55 833 0,09% Actions
Green Alpha Advisors, LLC $3 043 550 55 804 0,09% Actions
Walleye Trading LLC $3 005 154 55 100 0,09% Option d'achat
Caption Management, LLC $2 999 700 55 000 0,09% Option d'achat
MetLife Investment Management, LLC $2 958 413 54 243 0,09% Actions
BENJAMIN EDWARDS INC $2 956 845 54 216 0,09% Actions
Quantinno Capital Management LP $2 869 349 52 610 0,09% Actions
Cetera Investment Advisers $2 856 133 52 368 0,09% Actions
STATE OF WISCONSIN INVESTMENT BOARD $2 788 521 51 128 0,08% Actions
CITIGROUP INC $2 781 540 51 000 0,08% Option d'achat
CITIGROUP INC $2 781 540 51 000 0,08% Option de vente
WOLVERINE ASSET MANAGEMENT LLC $2 727 000 50 000 0,08% Option de vente
OSAIC HOLDINGS, INC. $2 693 150 49 381 0,08% Actions
Privium Fund Management B.V. $2 452 882 44 974 0,07% Actions
CANADA PENSION PLAN INVESTMENT BOARD $2 394 306 43 900 0,07% Actions
TUDOR INVESTMENT CORP ET AL $2 318 604 42 512 0,07% Actions

Initiés de la société 32 initiés · 12 dirigeants · 16 administrateurs

Dirigeant Rôle Dernière activité Actions détenues Achats 12m Ventes 12m Net 12m
Samarth Kulkarni Chief Executive Officer 20 mars 2026 M 255 501 0 9 $-10 756 932
Brendan Smith Chief Financial Officer 18 février 2023 M 5 072 0 0 $0
Michael John Tomsicek Chief Financial Officer 11 mars 2021 M 1 891 0 0 $0
Julianne Bruno Chief Operating Officer 20 mars 2025 M 10 544 0 0 $0
Lawrence Otto Klein CBO & COO 16 août 2022 A 26 797 0 0 $0
Naimish Patel Chief Medical Officer 29 mai 2026 A 19 357 1 2 $-312 892
James R. Kasinger General Counsel and Secretary 29 mai 2026 A 94 308 0 5 $-645 902
Phuong Khanh Morrow Chief Medical Officer 13 octobre 2023 A 4 411 0 0 $0
Tony W Ho Executive VP, Head of R&D 3 décembre 2021 M 52 364 0 0 $0
Tyler Dylan-Hyde Chief Legal Officer 16 janvier 2018 M 25 204 0 0 $0
Kala Subramanian Senior Vice President, Strategic Development and Operations 15 juin 2017 A — 0 0 $0
Sven Ante Lundberg Chief Scientific Officer 24 octobre 2016 C 505 617 0 0 $0
Christian Rommel Administrateur 5 juin 2026 A — 0 0 $0
Harold Edward Fleming Administrateur 5 juin 2026 A — 0 0 $0
Douglas A Treco Administrateur 5 juin 2026 A — 0 0 $0
Briggs Morrison Administrateur 5 juin 2026 A — 0 0 $0
Katherine A High Administrateur 5 juin 2026 A — 0 0 $0
Ali Behbahani Administrateur 5 juin 2026 A 14 0 0 $0
John Greene Administrateur 5 juin 2026 A 7 000 0 0 $0
Simeon George Administrateur 5 juin 2026 A 1 730 179 0 0 $0
Maria Fardis Administrateur 5 juin 2026 A — 0 0 $0
Sandesh Mahatme Administrateur 5 juin 2026 A — 0 0 $0
Bradley J Bolzon PhD Administrateur 9 juin 2022 A 148 831 0 0 $0
Pablo J Cagnoni Administrateur 19 novembre 2019 M 0 0 0 $0
Kurt Von Emster Administrateur 18 décembre 2018 S 1 171 268 0 0 $0
Thomas Woiwode Administrateur 15 juin 2018 A 640 014 0 0 $0
Anthony N Coles Administrateur 31 mai 2017 A 70 000 0 0 $0
CELGENE CORP /DE/ Détenteur de 10% 4 décembre 2017 S 3 722 534 0 0 $0
Hadley Harbor Master Investors (Cayman) L.P. Détenteur de 10% 24 octobre 2016 C 744 380 0 0 $0
GSK plc Détenteur de 10% 24 octobre 2016 C 3 220 627 0 0 $0
Raju Prasad — 7 août 2026 G 14 815 0 10 $-5 100 841
Rodger Novak — 30 juin 2021 S 573 007 0 0 $0

Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché

Activistes et détenteurs de 5%+ 6 participations

Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.

Déclarant Déposé Participation Statut Objectif Dépôt
Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 dépôts 16 février 2021 — Dépôt initial — SEC
GlaxoSmithKline plc ×5 dépôts 10 juillet 2020 — Dépôt initial — SEC
Bayer Global Investments B.V., Bayer AG ×4 dépôts 4 février 2020 — Dépôt initial — SEC
Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 dépôts 7 juin 2019 — Dépôt initial — SEC
CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 dépôts 8 février 2018 — Dépôt initial — SEC
Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 dépôts 16 janvier 2018 — Dépôt initial — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Détention d'ETF Détenu par 32 ETFs

Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.

Fonds Poids Unités Au Source
GNOM · Global X Funds 3,85% 38 191 NS 31 mai 2026 N-PORT
LABU · Direxion Shares ETF Trust 0,98% 97 235 NS 30 avril 2026 N-PORT
AVSC · AMERICAN CENTURY ETF TRUST 0,21% 104 016 NS 31 mai 2026 N-PORT
RSSL · Global X Funds 0,15% 39 589 NS 30 avril 2026 N-PORT
AVIE · AMERICAN CENTURY ETF TRUST 0,06% 108 NS 31 mai 2026 N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS 0,03% 3 509 NS 31 mai 2026 N-PORT
AVUS · AMERICAN CENTURY ETF TRUST 0,01% 15 609 NS 31 mai 2026 N-PORT
AVSU · AMERICAN CENTURY ETF TRUST 0,00% 289 NS 31 mai 2026 N-PORT
VXF · VANGUARD INDEX FUNDS — — 15 juillet 2026 Quotidien
VT · VANGUARD INTERNATIONAL EQUITY INDEX… — — 15 juillet 2026 Quotidien
VTWO · VANGUARD SCOTTSDALE FUNDS — — 15 juillet 2026 Quotidien
VTWV · VANGUARD SCOTTSDALE FUNDS — — 15 juillet 2026 Quotidien
VTWG · VANGUARD SCOTTSDALE FUNDS — — 15 juillet 2026 Quotidien
VTHR · VANGUARD SCOTTSDALE FUNDS — — 15 juillet 2026 Quotidien
ITOT · iShares Trust — — 22 juillet 2026 Quotidien
IWV · iShares Trust — — 18 août 2026 Quotidien
IWN · iShares Trust — — 14 août 2026 Quotidien
IWO · iShares Trust — — 18 août 2026 Quotidien
IWM · iShares Trust — — 18 août 2026 Quotidien
IBB · iShares Trust — — 18 août 2026 Quotidien
PDN · Invesco Exchange-Traded Fund Trust … — — 13 juillet 2026 Quotidien
OMFS · Invesco Exchange-Traded Self-Indexe… — — 13 juillet 2026 Quotidien
ESGV · VANGUARD WORLD FUND — — 30 juillet 2026 Quotidien
IYY · iShares Trust — — 7 août 2026 Quotidien
ISCB · iShares Trust — — 18 août 2026 Quotidien
ISCV · iShares Trust — — 29 juillet 2026 Quotidien
XT · iShares Trust — — 30 juillet 2026 Quotidien
SMLF · iShares Trust — — 10 août 2026 Quotidien
ESML · iShares Trust — — 14 août 2026 Quotidien
IDNA · iShares Trust — — 12 août 2026 Quotidien
WSML · iShares Trust — — 20 juillet 2026 Quotidien
IBBQ · Invesco Exchange-Traded Fund Trust … — — 20 juillet 2026 Quotidien